Goldman Sachs Maintains Sell on 10x Genomics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on 10x Genomics (NASDAQ:TXG) and reduced the price target from $30 to $26.
May 01, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on 10x Genomics and lowers the price target from $30 to $26.
The reduction in price target by a significant margin from $30 to $26 by Goldman Sachs, coupled with the maintenance of a Sell rating, suggests a bearish outlook on the stock. This could lead to negative sentiment among investors and potentially drive the stock price down in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100